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cumstances to assist the Agency’s determination of device safety
and effectiveness. One example is left ventricular assist device
(LVAD) therapy for end-stage heart failure. METHODS: Clini-
cal trials conducted in support of LVAD regulatory approval
have demonstrated mortality beneﬁts compared to optimal
medical therapy alone. However, signiﬁcant adverse events are
also typically observed, including sepsis, bleeding and stroke.
The regulatory challenge is to determine an acceptable tradeoff
between mortality and adverse events. In this regard, PRO’s
including quality of life measures could provide additional infor-
mation to assist in decision-making for device approval and 
also guide development of a more informative product label.
RESULTS: Three issues need to be addressed to boost the scien-
tiﬁc validity of PRO’s in heart failure device trials: 1) the inher-
ent unblinded study design for such devices makes PRO’s
susceptible to patient bias, confounding study results; 2) differ-
ential rates of follow-up between treatment arms: patients too
moribund to complete follow-up assessment tools might lead to
underreporting of negative HRQOL data and confound study
results; and 3) a consensus needs to be achieved regarding the
selection of valid assessment tools for heart failure studies. CON-
CLUSIONS: PRO’s have promise in heart failure device evalua-
tion, however, several important issues need to be addressed to
properly incorporate such measures in studies intended for reg-
ulatory approval. The FDA welcomes dialogue with the clinical,
academic and industry communities to develop appropriate PRO
measures for heart failure device therapy.
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OBJECTIVES: To predict students’ academic achievement (GPA)
by Self-efﬁcacy (SE). SE is deﬁned as the self-perception that one
can master a certain task or perform adequately in a given situ-
ation. METHODS: A descriptive cross-sectional survey was
employed for studying the relationship between Self-efﬁcacy and
academic achievement (GPA) of all (178) 5th year pharmacy stu-
dents at The College of Pharmacy, Chulalongkorn University,
Bangkok, Thailand during the period of August to September,
2003. RESULTS: The ﬁnal return rate of questionnaire was 171
(96.06%). The respondents average age was 22.02 years. Most
(124) were female (72.51%). The reliability coefﬁcient (Cron-
bach’s alpha) of Self-Efﬁcacy (SE) scale was 0.87. The ﬁndings
showed that there was positive relationship between SE and aca-
demic achievement (GPA) r = 0.38 (p = 0.03). The length of time
for preparing for an examination by a female was longer than
for a male (p = 0.03). There was no difference between male and
female SE (p = 0.07). However, female’s GPA was signiﬁcantly
higher than male’s (p = 0.02). SE of the Bangkoker students was
not different form the Non-Bangkoker students (p = 0.87). Stu-
dents who participated in activities had higher SE than students
who did not (p = 0.24) but the GPA of the two groups was not
different (p = 0.59). Attitude toward pharmacy profession had
no impact on SE nor GPA (p = 0.78, 0.82). The three predictors
of the model were SE, Gender, and Time (to prepare the exam-
ination) R square = 0.40, beta = 0.38, 0.10, and 0.07 (p = 0.02).
IQ was not controlled in this study. CONCLUSIONS: Self-Efﬁ-
cacy was a good predictor of academic achievement of Chula-
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OBJECTIVES: High Body Mass Index (BMI) and obesity, preva-
lent throughout industrialised societies, are known to be associ-
ated with many co-morbidities. A possible increase in upper
respiratory tract infections (URTI) associated with higher BMI
was investigated in this study. METHODS: Cohort study using
prospectively recorded patient data within the Full Feature
General Practice Research Database (GPRD) which represents
approximately 5% of UK population. Study subjects were cate-
gorised according to their baseline BMI into ﬁve exposure
groups: I 18.5–24.9; II 25.0–29.9; III 30.0–34.9; IV 35.0–39.9
and V 40.0 and above. BMI records of 50.0 and over were 
discarded. Patients were followed from January 1, 1998 until
December 31, 2002. Study outcomes were either Ear Nose and
Throat (ENT) infections, or Respiratory Tract Infections (RTI).
Statistical analysis: For each outcome group, crude incidence
rates and incidence rate ratios (IRR) by BMI category were esti-
mated. Poison regression analysis was used to make adjustments
for age, gender, asthma, COPD, diabetes, smoking status, GP
consultations and sleep apnoea. RESULTS: A total of 244,479
patients were eligible for the cohort. The adjusted IRR for ENT
infections and URTI respectively was for BMI group II, 1.13
(1.11, 1.15) and 1.10 (1.08, 1.12), for BMI group III, 1.18 (1.15,
1.21) and 1.21 (1.17, 1.24) BMI group IV, 1.23 (1.17, 1.28) and
1.33 (1.27, 1.39) and for BMI group V 1.29 (1.20, 1.38) and
1.42 (1.32, 1.53). These ﬁndings were consistent after stratiﬁca-
tion by the number of GP consultations in 1997. CONCLU-
SIONS: This study provides evidence that there is an association
between increasing BMI and ENT and upper respiratory tract
infection. This association should be taken into consideration in
the evaluation of the burden of obesity.
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OBJECTIVE: In Italy, the most recent report for the National
Institute of Statistics (ISTAT) indicate that 1/3 of Italians are
overweight an 1/10 obese, making the problem less dramatic
than in the UK, Germany or USA. The objectives of this prospec-
tive naturalistic study were to describe direct and indirect costs
attributable to the management of overweight and obesity and
to identify factors associated with costs of management of 
subjects with overweight and obese. METHODS: The study
included subjects between 18–65 years old with a body mass
index greater than 25 (BMI, deﬁned as weight in kilograms
divided by the square of height in meters). Our estimates of the
direct Health Care costs for the Italian National Health Care
Service (I-Nhs) refer to 399 subjects enrolled at 52 centers and
show a signiﬁcant increase in total and I-Nhs monthly costs with
increasing BMI. RESULTS: The increase in the average total
monthly costs between overweight (82€), mild (189€), moderate
(197€) and severe (233€) obese subjects was borderline signiﬁ-
cant (P = 0.051, Kruskall Wallis test). The increase in the average
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NHS monthly costs between overweight (47€), mild (128€),
moderate (162€) and severe (205€) obese subjects was signiﬁcant
(P = 0.02, Kruskall Wallis test). We found no statistically signif-
icant difference in out-of-pocket costs (P = 0.52). CONCLU-
SIONS: In few years the cost for the health care management of
a cohort of more than 5 millions of obese plus 15 millions of
overweight individuals in Italy is likely to become unbearable for
the I-Nhs, as it will be for most health systems. Policy makers
should give the highest priority to the identiﬁcation, promotion
and implementation of effective integrated programmes for the
prevention of obesity and overweight.
POB3
EVALUATION OF THE COST-UTILITY OF ORLISTAT
(XENICAL) IN THE UNITED KINGDOM
McEwan P1, Jones M1, Farina C2, Currie CJ3
1Cardiff University, Cardiff, Wales, UK; 2Roche Priducts Limited,
Welwyn Garden City, Hertfordshire, UK; 3Cardiff Research
Consortium, Cardiff, Wales, UK
OBJECTIVES: The health service impact of obesity is growing
relentlessly. There exist a small number of medical treatments 
for obesity. Obesity results in an increased risk of a plethora of
diseases. The purpose of this study was to evaluate the cost-
utility of orlistat (Xenical) in the UK. METHODS: A stochastic
simulation model was constructed using clinical trial and real-
life data comparing orlistat with no treatment and placebo under
various scenarios. The time duration was 2-years, 2003 prices
(UK£), costs discounted at 6%, beneﬁts 11/2% and evaluated
from an NHS perspective. Events were determined for only 
cardiovascular (CV) disease end points, and determined by
various risk functions. Utility was gained by a direct reduction
in obesity, survival and progression to CV events, including
microvascular events for diabetes. Costs were summed for events
and maintenance therapies. Extensive statistical economic analy-
sis and sensitivity analysis was undertaken. RESULTS: The cost
per quality adjusted life year (QALY) for orlistat versus no
treatment evaluating National Institute for Clinical Ecxellence
(NICE) guidelines was £12,814. The cost per QALY for orlistat
versus no treatment evaluating the product license was £13,045.
The cost per QALY for orlistat versus placebo evaluating 
NICE guidelines was £19,128. The cost per QALY for orlistat
versus no treatment evaluating the product license was £17,386.
These ﬁndings were fairly insensitive to variation in the main
parameters. CONCLUSIONS: These data, from a conservative
evaluation of the cost-utility of orlistat, showed that the treat-
ment is well within the cost-effectiveness threshold set by 
NICE (£20,000/QALY and £30,000/QALY). This analysis con-
tinues to support the positive guidance made by NICE in 2001
on orlistat.
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OBJECTIVES: Purpose of this study was to evaluate quality of
life (QoL) changes in MAP patients treated with orlistat accord-
ing to the product licence. Orlistat, a clinically-effective, cost-
effective treatment for weight reduction, is endorsed by NICE.
MAP, the patient support programme, is endorsed by the UK
Medicines Partnership project and provides direct support
through trained health care professionals to patients treated with
orlistat. METHODS: Patients starting treatment with orlistat
and enrolled in the MAP programme were recruited into this
study. Quality of life was measured using the 31-item, disease-
speciﬁc IWQOL-Lite: Impact of Weight on Quality of Life ques-
tionnaire comprising ﬁve scales assessing physical function,
self-esteem, sexual life, public distress, work and a total score.
Weight, height and body mass index (BMI) were also collected
at baseline, 3 and 6 months. Effect Size (ES) and Standardized
Response Means (SRM) were used to assess clinically meaning-
ful change for IWQOL-Lite subscales and total score, with values
interpreted as small (0.20–0.50), moderate (0.51–0.80) and large
(> = 0.81). RESULTS: All patients (n = 133) who achieved a
weight reduction of at least 5% at 3 months as stipulated by the
product licence were included in the analyses. Results of this
study showed that these patients achieved clinically meaningful
changes from baseline across all disease-speciﬁc QoL subscales,
with moderate changes from baseline in physical function (ES =
0.61; SRM = 0.77), and moderate to large changes from base-
line in self-esteem (ES = 0.66; SRM = 0.91) and IWQOL-Lite
total score (ES = 0.70; SRM = 0.94). CONCLUSIONS: These
ﬁndings clearly demonstrate that a weight reduction of at least
5% in patients taking orlistat enrolled in the MAP programme
translates into clinically signiﬁcant improvements across all
disease-speciﬁc QoL domains. It can therefore be concluded that
a combination of effective treatment with orlistat and direct
patient support provided by health care professionals through
the MAP programme results in clear beneﬁts for these patients.
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OBJECTIVES: Obesity increases the risk of chronic diseases,
with consequences on social cost and Quality of Life (QoL). Our
objective was to estimate the social cost and QoL in overweight,
obese and severe obese people. METHODS: A Cost-of-Illness
study was conducted from the societal perspective, adopting
three-month retrospective observational period. Data were col-
lected from a population based naturalistic survey investigating
cardiovascular risk factors in adult (40–79y.o.) Italian general
population. We selected normal weight people as control group
(Body Mass Index, BMI = 18.5–24.9), overweight (BMI =
25.0–29.9), obese (BMI = 30.0–34.9) and severe obese (BMI >
35.0) people, interviewed by general practitioners on
clinical/demographic characteristics, direct costs (drugs, hospi-
talisations, specialist visits, diagnostics exams) and indirect costs
(productivity loss). QoL was evaluated with the EQ-5D ques-
tionnaire. RESULTS: Data from 620 people were analyzed
(mean age = 58.2, 46.5% men). Total cost in overweight, obese
or severe obese people was quantiﬁed as twice than in normal
weight people (>200 vs. 111€/person/month). Direct cost
involved more than half of total expense: hospitalizations
accounted for the greatest part of direct cost, followed by drugs,
diagnostic exams, medical visits and laboratory exams. Globally,
the Visual Analogue Scale mean score was higher in overweight
than in normal weight people, and lower in obese and severe
obese people. Most of people reported no problem in “mobil-
ity”, “self care” and “usual activities” (around 90%), with
“pain/discomfort” and “anxiety/depression” (around 50%).
Very few people (<5%) reported extreme problems in any
